Clinical Trials
122 trialsAdoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
University of Pittsburgh
GENE
Sir Run Run Shaw Hospital
SEVILLA
UNICANCER
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Tongji Hospital
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
SHIELD
China Medical University, China
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
LenPac
National Health Research Institutes, Taiwan
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Peking Union Medical College Hospital
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
NIFE
AIO-Studien-gGmbH
XmAb20717 in Advanced Biliary Tract Cancers
Abramson Cancer Center at Penn Medicine
PILOT-BTC
Peking Union Medical College Hospital
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
The Second Affiliated Hospital of Shandong First Medical University
EMPIRE
Institut Bergonié
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Tongji Hospital
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
The Second Affiliated Hospital of Shandong First Medical University
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
SAIB
First Affiliated Hospital of Zhejiang University
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Tianjin Medical University Cancer Institute and Hospital
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shanghai Zhongshan Hospital
TisGCS for BTC
National Cheng-Kung University Hospital
DEBATE
Asan Medical Center
OPTIMUM
Asan Medical Center
ESR-22-21719
Georgetown University
NEOLANGIO
University Health Network, Toronto
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
RADITOP
Shanghai Zhongshan Hospital
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Harbin Medical University